Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593331 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance
A Phase 1 study of Insulin Resistance, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 79
- Enrollment target
- 1
- Study location
NCT02593331: Completed Phase 1 study of Insulin Resistance, sponsored by Genentech.
NCT02593331 is a Phase 1 study of Insulin Resistance that has completed, run by Genentech. The registered enrollment target is 79 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02593331, a Phase 1 study of Insulin Resistance, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 79 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and tolerability profile of BFKB8488A following subcutaneous (SC) administration in overweight and obese participants (body mass index \[BMI\] greater than \[\>\] 27 to less than or equal to \[\</=\] 40 kilograms per square meter \[kg/m\^2\]) with markers of insulin resistance. Single ascending fixed doses of BFKB8488A will be evaluated. Participants will be randomized into 7 sequential ascending fixed-dose cohorts of BFKB8488A SC or placebo and safety reviews will be performed before escalation to higher dose cohorts. Additionally, following the ascending fixed-dose SC cohorts, a separate cohort will open to evaluate the PK of BFKB8488A after intravenous (IV) administration.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG BFKB8488A
Study Locations (1)
California
- Profil Institute for Clinical Research Inc. - Chula Vista
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2015-10-29 |
| Est. Completion | 2017-03-28 |
| Phase | Phase 1 |
What the finished NCT02593331 record still lists
NCT02593331 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Insulin Resistance appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02593331 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02593331 about?
NCT02593331 is a clinical study titled "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance". This study will evaluate the safety and tolerability profile of BFKB8488A following subcutaneous (SC) administration in overweight and obese participants (body mass index \[BMI\] greater than \[\>\] 27 to less than or equal to \[\</=\] 40 kilograms per square meter \[kg/m\^2\]) with markers of insul...
What is the current status of trial NCT02593331?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2015-10-29. Estimated completion is 2017-03-28.
What conditions does trial NCT02593331 study?
This clinical trial studies the following conditions: Insulin Resistance.
What interventions are being tested in trial NCT02593331?
The interventions under investigation include: Placebo (OTHER), BFKB8488A (DRUG).
Who is sponsoring clinical trial NCT02593331?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02593331 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02593331's enrollment target sits among peer trials
79 34th of 120 higher than 87 of 120 other Insulin Resistance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
-
Graded Insulin Suppression Test P&F
RECRUITING · Phase 1
-
Diazoxide Suppression Test P&F Study
RECRUITING · Phase 1
-
Mitigating the Pro-inflammatory Phenotype of Obesity
RECRUITING · Phase 1
-
Human Models of Selective Insulin Resistance: Alpelisib, Part I
RECRUITING · Phase 1
-
Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI